Erste Asset Management GmbH Buys 27,098 Shares of Thermo Fisher Scientific Inc. $TMO

Erste Asset Management GmbH raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 44.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 87,868 shares of the medical research company’s stock after purchasing an additional 27,098 shares during the quarter. Erste Asset Management GmbH’s holdings in Thermo Fisher Scientific were worth $51,144,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of TMO. High Note Wealth LLC raised its stake in shares of Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after acquiring an additional 29 shares in the last quarter. Beacon Financial Strategies CORP purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $29,000. Olistico Wealth LLC purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $29,000. Core Wealth Advisors LLC purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $30,000. Finally, HFM Investment Advisors LLC raised its stake in shares of Thermo Fisher Scientific by 341.7% during the fourth quarter. HFM Investment Advisors LLC now owns 53 shares of the medical research company’s stock worth $31,000 after acquiring an additional 41 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the transaction, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. The trade was a 1.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on TMO. Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Wednesday, April 8th. Wells Fargo & Company decreased their price target on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. DZ Bank began coverage on shares of Thermo Fisher Scientific in a research note on Friday, March 27th. They set a “buy” rating and a $610.00 price target on the stock. Morgan Stanley reissued an “overweight” rating and set a $620.00 price target on shares of Thermo Fisher Scientific in a research note on Monday, April 27th. Finally, Barclays decreased their target price on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 14th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $613.67.

Thermo Fisher Scientific Stock Up 0.0%

Shares of Thermo Fisher Scientific stock opened at $472.98 on Monday. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. The company’s fifty day simple moving average is $479.94 and its two-hundred day simple moving average is $530.83. The company has a market cap of $175.77 billion, a P/E ratio of 26.00, a PEG ratio of 2.09 and a beta of 0.88. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. The business had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, June 15th. Thermo Fisher Scientific’s payout ratio is presently 10.34%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.